United Kingdom-based biotechnology firm Oxford Cannabinoid Technologies (OCT) announced the appointment of Dr. Valentino Parravicini, PhD, as their new Chief Scientific Officer (CSO).
United Kingdom-based biotechnology firm Oxford Cannabinoid Technologies (OCT), which researches using cannabinoids to treat acute and chronic health conditions, announced the appointment of Dr. Valentino Parravicini, PhD, as their new Chief Scientific Officer (CSO). With this new position, Parravicini will help support OCT’s goal of developing cannabinoid-based prescription medicine for ailments ranging from oncology and pain to immunology and neurology.
Parravicini has a lengthy and distinguished career in the medical fields of oncology, immunology, and inflammation. He has led revolutionary in vitro and in vivo projects as well as initiated award-winning work in the fields of pharma and biotech.
“I am delighted to be joining the team at Oxford Cannabinoid Technologies whose reputation precedes them,” said Parravicini in the company’s press release (1). “OCT’s search for transformative therapies to meet currently unmet medical needs is a perfect match with my past professional experience and my unquenchable desire to see how we can best harness cannabinoids to transform the lives of millions of people so that they live longer, more active lives.”
“We are thrilled to have Valentino come on board. He has exactly the right kinds of skills sets that we need to help take OCT on the next stage of its exciting journey,” said John Lucas, Chief Commercial Officer of OCT (1). “This is a time of extraordinary and dynamic change and innovation in our sector and we are delighted to have him at our side to help us be that change and make it come alive for millions of sufferers around the world.”
Parravicini will be overseeing OCT’s drug discovery and development studies, which include the preclinical development of OCT461201—the company’s lead, highly selective and potent CB2 agonist. OCT461201 is suspected to be a potentially effective treatment for irritable bowel syndrome (IBS) and other various diseases. Aside from research trials, Parravicini will be working with OCT’s lead business and research partners and also looking into developing new research partnerships with other leading academic and commercial institutions located around the world.